Drug Type TCR therapy |
Synonyms GSK 4427296, GSK4427296 |
Target |
Mechanism NY-ESO-1 modulators(Cancer/testis antigen 1 modulators) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | US | 21 Dec 2020 | |
Advanced Malignant Solid Neoplasm | Phase 1 | AU | 21 Dec 2020 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CA | 21 Dec 2020 | |
Advanced Malignant Solid Neoplasm | Phase 1 | DE | 21 Dec 2020 | |
Advanced Malignant Solid Neoplasm | Phase 1 | NL | 21 Dec 2020 | |
Advanced Malignant Solid Neoplasm | Phase 1 | SE | 21 Dec 2020 | |
LAGE-1a Positive Solid Tumors | Phase 1 | US | 21 Dec 2020 | |
LAGE-1a Positive Solid Tumors | Phase 1 | AU | 21 Dec 2020 | |
LAGE-1a Positive Solid Tumors | Phase 1 | CA | 21 Dec 2020 | |
LAGE-1a Positive Solid Tumors | Phase 1 | DE | 21 Dec 2020 |